');
} else {
var query = elem.find('.keywords').html();
$.ajax({
context: elem,
url: 'https://wn.com/api/upge/cheetah-search-adv/video',
cache: true,
data: {
'query': query
},
dataType: 'jsonp',
success: function(text) {
if (text.length > 0) {
video_id = text[0].id;
elem.find('.player').html('
');
}
}
});
}
}
var stopAllYouTubeVideos = function() {
var iframes = document.querySelectorAll('iframe');
Array.prototype.forEach.call(iframes, function(iframe) {
iframe.contentWindow.postMessage(JSON.stringify({ event: 'command', func: 'pauseVideo' }), '*');
});
}
jQuery(function() {
jQuery(".playVideo").live("click", function() {
if(!$(this).hasClass("played")){
stopAllYouTubeVideos();
var elem = $(this);
setTimeout(function(){
mouseOverMe(elem);
}, 1000);
}
});
jQuery(".description_box .expandContent").live("click", function() {
elem = $(this).parent().parent().parent().find('.descContent');
if(elem.height() > 51) {
elem.css('height', '44px');
$(this).html('Show More
');
}else{
elem.css('height', 'auto');
$(this).html('Hide
');
}
});
jQuery('.interview-play-off').click(function() {
$(".interview-play-off").hide();
$(".interview-play").show();
$(".videoplayer-control-pause").click();
});
jQuery(".video-desc .show_author_videos").live("click", function() {
query = $(this).attr('title');
container = $(this).parent().parent().parent().find('.video-author-thumbs');
$(this).parent().parent().parent().find('.video-author-thumbs').css('height', '220px');
jQuery.ajax({
url: '/api/upge/cheetah-photo-search/videoresults',
data: {'query': query},
success: function(text) {
if(!text) { text = i18n("No results"); }
container.html(jQuery(text));
}
});
});
});
// -->
Latest News for: alk
Edit
GetNews
26 Mar 2026
ALK Inhibitors Overview ... The pathogenesis of several cancers is closely related to aberrant forms of ALK or aberrant ALK expression, including ALK fusion proteins, ALK-activated point mutations, and ALK amplification ... ALK Inhibitors Companies.
Edit
Pharmiweb
25 Mar 2026
... glue degrader targeting ALK fusion proteins. LEXINGTON, Mass.--(BUSINESS WIRE)--#ALK--TRIANA Biomedicines, Inc ... “TRI-611 was designed as an innovative therapeutic approach to target ALK fusion proteins.
Edit
Pharmiweb
19 Mar 2026
LEXINGTON, Mass.--(BUSINESS WIRE)--#ALK--TRIANA Biomedicines, Inc ... ALK+ NSCLC represents an important subset of lung cancer, characterized by a dependence on ALK fusion proteins for its growth and survival.
Edit
Public Technologies
05 Feb 2026
A pilot site for ALK's low-carbon transition in Europe ... After analysing the site's technical requirements and constraints, SPIE proposed four scenarios to ALK to reduce CO2 emissions and optimise the site's energy consumption.